查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2006253

CRISPR技术市场：按交付方式、应用和最终用户划分－2026-2032年全球市场预测

CRISPR Technology Market by Offering, Delivery Method, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，CRISPR 技术市场价值将达到 40.2 亿美元，到 2026 年将成长至 45.7 亿美元，到 2032 年将达到 103.2 亿美元，复合年增长率为 14.41%。

主要市场统计数据
基准年 2025 40.2亿美元
预计年份：2026年 45.7亿美元
预测年份 2032 103.2亿美元
复合年增长率 (%) 14.41%

本文简要概述了 CRISPR 的科学基础和转化研究轨迹，阐明了其技术支柱、法规环境和商业性意义。

CRISPR 工具包融合了分子生物学、电脑设计和转化研究，能够对多种生物的基因组进行精确编辑。酵素工程、引导 RNA 优化、递送技术和筛检平台等方面的进步，共同推动了 CRISPR 从一项实验室技术发展成为应用生命科学的核心能力。随着基础科学发现的不断成熟，研究机构和企业正日益致力于将基因编辑应用于治疗方法、农业改良、诊断和工业生物製程等领域。

核酸酶、引导设计和递送系统的技术进步如何重新定义 CRISPR 价值炼和应用趋势？

CRISPR技术的未来正经历着一场变革性的转变，这主要得益于酵素的多样化、电脑辅助引导RNA设计的整合以及先进递送系统的创新。新开发的核酸酶和碱基编辑器拓展了可编辑的基因类型，而引导RNA化学性质的改进和演算法设计的进步则提高了特异性并减少了脱靶效应。同时，脂质体製剂、标靶化病毒载体和体外细胞修饰等递送策略正在拓展CRISPR技术在治疗和农业领域的应用范围，进而重塑其价值链。

我们将评估美国近期关税措施对 CRISPR 供应链、采购和製造决策的一系列营运和策略影响。

美国近期实施的关税措施和贸易政策调整，为全球CRISPR供应链引入了新的变数，影响了试剂、仪器和外包服务的筹资策略。进口关税的提高以及相关的合规要求可能会增加海外采购组件的总体成本，给研究机构和製造商带来行政负担。为此，许多相关人员正在重新审视与供应商的关係，将采购来源多元化，转向其他地区，并增加库存以应对价格波动。

将产品和服务组合、交付方式、应用领域和最终用户概况与营运风险和策略重点连结起来的多维細項分析。

从实际观点进行市场细分，可以清楚了解每种产品/服务、交付方式、应用领域和最终用户的价值和风险集中在哪里。基于产品/服务，市场可分为「产品」与「服务」两大类。产品类包括酵素、引导RNA、试剂盒和试剂等核心组件，而服务类则包括细胞株建构、gRNA设计和载体建构等实验室功能，以及将平台潜力转化为实验结果的筛检服务。这种产品/服务的区分有助于企业优先考虑对内部能力和外部专业知识的投资。

美洲、欧洲、中东和非洲以及亚太地区的法规环境、人才库和製造地对 CRISPR 采用和合作策略的影响。

区域趋势影响人才获取、监管路径、供应链韧性和伙伴关係系统。美洲拥有大规模研究型大学、创业投资集群和完善的临床试验基础设施，在治疗药物的研发和商业化方面正蓬勃发展。该地区的生态系统优先考虑将有前景的治疗方法快速转化为早期临床研究，并倾向于支持学术发明者和商业伙伴之间的深度合作。

深入了解试剂开发商、服务提供者和策略合作伙伴如何建立能力、合作伙伴关係和卓越运营，以推动 CRISPR 专案。

主要企业的发展趋势凸显了各组织如何将技术能力转化为市场吸引力。成熟的核心试剂和设备开发人员持续投资于酵素工程、试剂品管和可扩展试剂盒设计，以满足科研实验室和受监管开发项目的需求。同时，专业服务供应商正透过整合gRNA设计、载体建构、细胞株工程和高通量筛检等服务来脱颖而出，帮助客户缩短药物研发週期。

为产业领导者提供可操作的策略重点，以建立韧性能力、实现供应链多元化并加速负责任地实用化CRISPR 创新技术。

寻求永续竞争优势的领导企业应采取平衡策略，将能力建构与风险规避结合。首先，企业应优先发展内部模组化能力，以应对酵素品管和gRNA检验等关键路径活动，同时将专业化或规模依赖职能外包给值得信赖的服务供应商。这种混合模式既能保持灵活性，又能有效控制知识产权和技术标准。

为了支持实际见解，我们采用严格的混合方法研究途径，结合专家访谈、文献整合和以可重复性为重点的资料检验。

本调查方法融合了初步研究、专家访谈和系统性文献整合，以产生严谨客观的分析。初步研究包括与学术界、生物技术公司、受託研究机构和製药研发公司的技术领导者进行结构化访谈，以了解实际营运中的限制和不断变化的需求。专家访谈则提供了关于酵素创新、递送挑战和监管趋势的深入定性分析，从而能够将实践者的观点与文献证据进行比较。

整合 CRISPR 在科学、操作和监管方面的成熟度，并确定当前面临的挑战和短期实用化。

CRISPR技术已从一项突破性的科学发现发展成为一个基础平台，其具体实用化途径涵盖治疗、农业、诊断和工业生物技术等领域。儘管酶工程、引导序列设计、递送方法和整合服务的进步降低了技术门槛，但在递送特异性、监管合规性和供应链韧性方面仍然存在挑战。随着应用范围的扩大，技术、监管和商业性因素的相互作用将决定哪些应用能够率先达到临床和市场成熟阶段。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 CRISPR技术市场：依产品/服务分类

  • 产品
    • 酵素
    • 引导RNA
    • 试剂盒和试剂
  • 服务
    • 细胞株工程
    • gRNA设计与载体构建
    • 筛检服务

第九章 CRISPR技术市场：依交付方式划分

  • Ex Vivo
    • 细胞株改造
    • 原代细胞修饰
  • In vivo
    • 直接编辑
    • 奈米颗粒递送
    • 重定向载体

第十章 CRISPR技术市场：按应用划分

  • 农业用途
    • 畜牧养殖
    • 抗虫害
  • 生物医学应用
    • 药物发现与开发
    • 基因治疗
  • 诊断
  • 工业生物技术
    • 生质燃料生产
    • 微生物菌株的改造

第十一章：CRISPR技术市场：依最终用户划分

  • 学术和研究机构
  • 生技公司
  • 合约研究机构
  • 製药公司

第十二章：CRISPR技术市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：CRISPR技术市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：CRISPR技术市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 美国CRISPR技术市场

第十六章 中国CRISPR技术市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AgBiome Inc.
  • Agilent Technologies, Inc.
  • BASF SE
  • Bayer AG
  • Beam Therapeutics Inc.
  • Benson Hill Biosystems, Inc.
  • Caribou Biosciences, Inc.
  • Cibus Inc.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • GeneCopoeia, Inc.
  • Genscript Biotech Corporation
  • Hera BioLabs
  • Intellia Therapeutics Inc.
  • Lonza Group Ltd.
  • Mammoth Biosciences, Inc.
  • Merck KGaA
  • Pairwise Foods Inc.
  • Qiagen NV
  • Revvity, Inc.
  • Syngenta AG
  • Thermo Fisher Scientific, Inc.
  • ToolGen Inc,
  • Yield10 Bioscience, Inc.
Product Code: MRR-B1685377A648

The CRISPR Technology Market was valued at USD 4.02 billion in 2025 and is projected to grow to USD 4.57 billion in 2026, with a CAGR of 14.41%, reaching USD 10.32 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.02 billion
Estimated Year [2026] USD 4.57 billion
Forecast Year [2032] USD 10.32 billion
CAGR (%) 14.41%

A concise overview of CRISPR's scientific foundations and translational trajectory that frames technological pillars, regulatory context, and commercial relevance

The CRISPR toolkit sits at the intersection of molecular biology, computational design, and translational research, enabling precise edits of genomes across diverse organisms. Advancements in enzyme engineering, guide RNA optimization, delivery modalities, and screening platforms have collectively moved CRISPR from a laboratory technique into a core capability for applied life sciences. As basic science discoveries have matured, institutions and companies are increasingly focused on translating gene editing into therapeutics, agricultural improvements, diagnostics, and industrial bioprocessing.

This introduction frames the report's scope by highlighting the technical pillars-nuclease chemistry, guide design, reagent quality, and delivery strategies-that underpin performance and adoption. It also situates CRISPR within an evolving ecosystem of regulatory scrutiny, ethical debate, and supply chain dynamics. Readers should expect an evidence-based synthesis that balances molecular detail with commercial realities, supporting informed choices across research, product development, and strategic investment.

How converging technological advances in nucleases, guide design, and delivery systems are redefining the CRISPR value chain and adoption dynamics

The landscape of CRISPR technology is undergoing transformative shifts driven by converging innovations in enzyme diversification, computational guide design, and sophisticated delivery systems. New engineered nucleases and base editors have expanded the repertoire of achievable edits, while advances in guide RNA chemistry and algorithmic design are improving specificity and reducing off-target effects. In parallel, delivery strategies such as lipid nanoparticle formulations, retargeted viral vectors, and ex vivo cell modification approaches are enabling broader therapeutic and agricultural applications, thereby reshaping the value chain.

Concurrently, institutional adoption patterns are changing: academic groups, biotech companies, contract research organizations, and pharmaceutical developers are reallocating resources to integrate CRISPR into pipelines for drug discovery, cell therapies, diagnostic assays, and strain engineering. Strategic collaborations and licensing arrangements are increasingly common as organizations seek to combine platform strengths with clinical or commercialization expertise. Regulatory frameworks and public discourse around ethical use are also maturing, prompting companies to invest in compliance, transparency, and stakeholder engagement to accelerate responsible deployment.

Evaluating the cascading operational and strategic effects of recent United States tariff actions on CRISPR supply chains, procurement, and manufacturing decisions

Recent tariff measures and trade policy adjustments implemented by the United States have introduced new variables into global CRISPR supply chains, affecting procurement strategies for reagents, instruments, and outsourced services. Elevated import duties and related compliance requirements can increase landed costs for components sourced internationally and create administrative overhead for research organizations and manufacturers. In response, many stakeholders are reassessing supplier relationships, diversifying procurement to alternate geographies, and increasing inventories to buffer against volatility.

The tariff environment also influences strategic location decisions for manufacturing and service activities. Companies that rely on specialized enzymes, guide RNA synthesis, or kits and reagents may accelerate efforts to localize production or to develop alternative sourcing models, including partnerships with contract manufacturers within tariff-favored jurisdictions. Importantly, the cumulative impact extends beyond pricing: it reshapes contractual terms, lengthens lead times for critical inputs, and can alter timelines for development programs. Consequently, organizations with international operations are prioritizing supply chain transparency, scenario planning, and contract clauses that mitigate tariff exposure while preserving research continuity.

A multidimensional segmentation analysis linking product and service portfolios, delivery approaches, application areas, and end-user profiles to operational risks and strategic priorities

A practical segmentation perspective clarifies where value and risk concentrate across offerings, delivery modalities, applications, and end users. Based on offering, the landscape divides into Product and Services: Product pathways encompass core components such as enzymes, guide RNA, and kits & reagents, while Services include laboratory capabilities like cell line engineering, gRNA design & vector construction, and screening services that convert platform potential into experimental outcomes. These offering distinctions help organizations prioritize investments in in-house capabilities versus outsourced expertise.

Based on delivery method, distinctions between Ex Vivo and In Vivo approaches shape technical and regulatory requirements. Ex Vivo strategies further segment into cell line modification and primary cell modification, each with unique manufacturing, cell handling, and quality control needs. In Vivo delivery subdivides into direct editing, nanoparticle delivery, and retargeting vectors, where biodistribution, immunogenicity, and long-term expression profiles inform development choices. Based on application, CRISPR use cases span agricultural applications, biomedical applications, diagnostics, and industrial biotechnology; agricultural efforts include livestock breeding and pest resistance, biomedical efforts emphasize drug discovery & development and gene therapy, and industrial biotechnology focuses on biofuel production and microbial strain engineering. Based on end-user, demand originates from academic & research institutes, biotech companies, contract research organizations, and pharmaceutical companies, each bringing different procurement cycles, validation expectations, and collaboration models. Collectively, these segmentation lenses reveal where technical complexity, regulatory friction, and commercial opportunity overlap, guiding prioritization of capability building and partnership formation.

How regional regulatory environments, talent pools, and manufacturing hubs across the Americas, Europe Middle East & Africa, and Asia-Pacific shape CRISPR adoption and collaboration strategies

Regional dynamics influence talent access, regulatory pathways, supply chain resilience, and partnership ecosystems. In the Americas, home to large research universities, venture capital concentration, and established clinical trial infrastructures, there is strong momentum for therapeutic development and commercialization. The region's ecosystem tends to favor rapid translation of promising modalities into early-stage clinical work and to support deep collaborations between academic inventors and commercial partners.

Europe, Middle East & Africa present a heterogeneous environment where divergent regulatory regimes and public attitudes shape program design. Several European jurisdictions combine robust scientific capabilities with conservative regulatory evaluation, prompting companies to adopt deliberate engagement strategies and to invest in transparent safety data. Meanwhile, Middle Eastern and African markets show growing interest in agricultural and industrial biotechnology applications, with an emphasis on capacity building. Asia-Pacific exhibits a mix of rapid technical adoption, localized manufacturing strengths, and significant government-backed initiatives to support biotechnology. The region's expansive manufacturing base for reagents and instruments, coupled with advancing clinical capabilities, positions it as a critical node for both supply and collaborative development.

Insights into how reagent developers, service specialists, and strategic partners are structuring capabilities, alliances, and operational excellence to advance CRISPR programs

Key corporate behaviors illuminate how organizations translate technological capability into market traction. Established developers of core reagents and instruments continue to invest in enzyme engineering, reagent quality control, and scalable kit design to meet the demands of both research labs and regulated development programs. Parallel to this, specialized service providers are differentiating through integrated offerings that combine gRNA design, vector construction, and cell line engineering with high-throughput screening, enabling customers to compress discovery timelines.

Strategic alliances and licensing arrangements remain central to scaling complex therapeutic programs, with companies forming cross-sector partnerships to access clinical expertise, manufacturing capacity, or regulatory experience. Contract research organizations and contract manufacturing organizations demonstrate increasing vertical integration, offering end-to-end support from assay development through GMP production. Firms that prioritize robust quality management systems, transparent data packages, and regulatory engagement gain trust from pharmaceutical sponsors and academic collaborators, reinforcing their role in translational pipelines. Taken together, these behaviors underscore that commercial success hinges on technical excellence plus the operational capabilities to support regulated development pathways.

Actionable strategic priorities for industry leaders to build resilient capabilities, diversify supply chains, and accelerate responsible translation of CRISPR innovations

Leaders seeking sustainable advantage should adopt a balanced playbook that combines capability investment with risk mitigation. First, organizations should prioritize modular in-house capabilities for critical-path activities such as enzyme quality control and gRNA validation while outsourcing specialized or scale-dependent functions to trusted service providers. This hybrid approach preserves control over intellectual property and technical standards while enabling agility.

Second, proactively harden supply chains by diversifying suppliers across jurisdictions and by qualifying secondary sources for high-risk inputs. Third, invest in regulatory intelligence and early engagement with authorities to align study designs, safety assessments, and manufacturing controls with evolving expectations. Fourth, cultivate partnerships that pair scientific novelty with clinical or commercial experience, ensuring that platform innovations translate into viable products. Finally, embed data governance, reproducibility practices, and transparent reporting into R&D workflows to build credibility with regulators, funders, and the public. Together, these actions create a resilient foundation for scaling CRISPR-enabled initiatives responsibly and efficiently.

A rigorous mixed-methods research approach combining expert consultations, literature synthesis, and reproducibility-focused data validation to underpin actionable insights

The research methodology integrates primary engagement, expert interviews, and systematic literature synthesis to generate a rigorous, objective analysis. Primary engagement included structured consultations with technical leaders across academia, biotechnology firms, contract research organizations, and pharmaceutical developers to capture real-world operational constraints and evolving requirements. Expert interviews provided qualitative depth on enzyme innovations, delivery challenges, and regulatory trajectories, enabling the study to triangulate practitioner perspectives with documented evidence.

Secondary research encompassed peer-reviewed scientific literature, regulatory guidance documents, patent landscapes, and publicly disclosed corporate materials to map technological progress and institutional behavior. Data synthesis emphasized reproducibility, cross-validation of claims, and contextual interpretation of technical performance metrics. Throughout the process, methodological safeguards were applied to minimize bias, including diverse expert sampling and transparent citation of sources used to inform technical assessments. The resulting methodology supports conclusions that are actionable for scientific, operational, and strategic audiences.

A synthesis of CRISPR's maturation across scientific, operational, and regulatory dimensions that identifies enduring challenges and near-term enablers of translation

CRISPR technology has progressed from a transformative scientific discovery to a foundational platform with tangible translational pathways across therapeutics, agriculture, diagnostics, and industrial biotechnology. Progress in enzyme engineering, guide design, delivery modalities, and integrated services has reduced technical barriers, yet persistent challenges remain in delivery specificity, regulatory alignment, and supply chain resilience. As adoption broadens, the interplay of technical, regulatory, and commercial considerations will determine which applications reach clinical and market maturity first.

Looking forward, stakeholders that invest in robust quality systems, diversify procurement strategies, and engage early with regulatory authorities will be best positioned to convert platform capability into sustainable products. Moreover, strategic partnerships that combine deep technical expertise with clinical development capacity will accelerate translation while distributing risk. In sum, CRISPR stands as a high-impact platform whose realized value will depend on coordinated advances in science, operations, and governance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CRISPR Technology Market, by Offering

  • 8.1. Product
    • 8.1.1. Enzymes
    • 8.1.2. Guide RNA
    • 8.1.3. Kits & Reagents
  • 8.2. Services
    • 8.2.1. Cell Line Engineering
    • 8.2.2. gRNA Design & Vector Construction
    • 8.2.3. Screening Services

9. CRISPR Technology Market, by Delivery Method

  • 9.1. Ex Vivo
    • 9.1.1. Cell Line Modification
    • 9.1.2. Primary Cell Modification
  • 9.2. In Vivo
    • 9.2.1. Direct Editing
    • 9.2.2. Nanoparticle Delivery
    • 9.2.3. Retargeting Vectors

10. CRISPR Technology Market, by Application

  • 10.1. Agricultural Applications
    • 10.1.1. Livestock Breeding
    • 10.1.2. Pest Resistance
  • 10.2. Biomedical Applications
    • 10.2.1. Drug Discovery & Development
    • 10.2.2. Gene Therapy
  • 10.3. Diagnostics
  • 10.4. Industrial Biotechnology
    • 10.4.1. Biofuel Production
    • 10.4.2. Microbial Strain Engineering

11. CRISPR Technology Market, by End-User

  • 11.1. Academic & Research Institutes
  • 11.2. Biotech Companies
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical Companies

12. CRISPR Technology Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. CRISPR Technology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. CRISPR Technology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States CRISPR Technology Market

16. China CRISPR Technology Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AgBiome Inc.
  • 17.6. Agilent Technologies, Inc.
  • 17.7. BASF SE
  • 17.8. Bayer AG
  • 17.9. Beam Therapeutics Inc.
  • 17.10. Benson Hill Biosystems, Inc.
  • 17.11. Caribou Biosciences, Inc.
  • 17.12. Cibus Inc.
  • 17.13. CRISPR Therapeutics AG
  • 17.14. Danaher Corporation
  • 17.15. Editas Medicine, Inc.
  • 17.16. GeneCopoeia, Inc.
  • 17.17. Genscript Biotech Corporation
  • 17.18. Hera BioLabs
  • 17.19. Intellia Therapeutics Inc.
  • 17.20. Lonza Group Ltd.
  • 17.21. Mammoth Biosciences, Inc.
  • 17.22. Merck KGaA
  • 17.23. Pairwise Foods Inc.
  • 17.24. Qiagen NV
  • 17.25. Revvity, Inc.
  • 17.26. Syngenta AG
  • 17.27. Thermo Fisher Scientific, Inc.
  • 17.28. ToolGen Inc,
  • 17.29. Yield10 Bioscience, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CRISPR TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CRISPR TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GUIDE RNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GUIDE RNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GUIDE RNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GRNA DESIGN & VECTOR CONSTRUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GRNA DESIGN & VECTOR CONSTRUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GRNA DESIGN & VECTOR CONSTRUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SCREENING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SCREENING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SCREENING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE MODIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE MODIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE MODIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIRECT EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIRECT EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIRECT EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY RETARGETING VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY RETARGETING VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY RETARGETING VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY LIVESTOCK BREEDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY LIVESTOCK BREEDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY LIVESTOCK BREEDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PEST RESISTANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PEST RESISTANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PEST RESISTANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOFUEL PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOFUEL PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOFUEL PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY MICROBIAL STRAIN ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY MICROBIAL STRAIN ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY MICROBIAL STRAIN ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 210. GCC CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 212. GCC CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 213. GCC CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 214. GCC CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 215. GCC CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 216. GCC CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 217. GCC CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. GCC CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 219. GCC CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. GCC CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 246. G7 CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 248. G7 CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 249. G7 CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 250. G7 CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 251. G7 CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 252. G7 CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 253. G7 CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. G7 CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. G7 CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 258. NATO CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 260. NATO CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 261. NATO CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 262. NATO CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 263. NATO CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 264. NATO CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 265. NATO CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. NATO CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 267. NATO CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. NATO CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)